SPX -0.34% VIX 1.42%
HOUSE DEMOCRATS VOTE TO CONDEMN TRUMPS RACIST TWEETS 
STOCKS END LOWER, RETREATING FROM RECORDS AFTER TRUMP STOKES TRADE UNCERTAINTY 
U.S. MANUFACTURING IS IN RECESSION: FED DATA 
TESLA DROPS CHEAPER MODEL S, MODEL X OPTIONS 
SHORT COVERING PLAYS PART AS BLUE APRON ROCKETS 50% ON BEYOND MEAT NEWS 
HBOS GAME OF THRONES GETS RECORD-BREAKING 32 EMMY NOMINATIONS 
TRUMP AGREES WITH ALLY AND FACEBOOK BOARD MEMBER THAT GOOGLE SHOULD BE PROBED 
THINK YOUR INCOME LEVEL IS TOO HIGH FOR A ROTH IRA? THINK AGAIN 
GOLDMAN SACHS SHARES HELP DOW MAINTAIN INTRADAY GAIN 
DOW TAPS ALL-TIME INTRADAY HIGH AS INVESTORS WEIGH BIG-BANK EARNINGS 
Wed, Jul 17 4:44am


Biogen Inc [BIIB]
$231.55 2.07 (0.89%)

BIIB Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 44.87 Billion
BIIB Description

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.


Visit Website

BIIB Earnings

EPS 7.17 P/E Ratio 10.77
Previous Earnings Wed, Apr 24, 2019
Latest Earnings Tue, Jul 23, 2019 (In 6 days)

BIIB Dividend

Yield --
Ex-Date --
Pay Date --
History --

BIIB Charts

$216.49
52 Week Range
$388.67
Mar 22, 2019
Jul 25, 2018



Symbol Price Day % YTD %
BIIB $231.55 -0.89% -24.00%

Symbol Surfing

How can we make Symbol Surfing better?

info@symbolsurfing.com

Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.



©2019 Symbol Surfing All Rights Reserved.

Cookies Policy | Terms Of Service | Privacy Policy